Search

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release: DelveInsight's 'Follicular Lymphoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline follicular lymphoma therapies in various [...]

DUBLIN: Research and Markets has issued the following news release: The 'B-cell Lymphoma - Pipeline Insight, 2024' clinical trials has been added to ResearchAndMarkets.com's offering. This 'B-cell Lymphoma- Pipeline Insight, [...]

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release: DelveInsight's 'NK Cell Therapy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline NK cell therapies in [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global [...]

Chicago: Sidley Austin has issued the following press release: Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following press release: Nektar Therapeutics (Nasdaq: NKTR) today announced several presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology [...]

SAN DIEGO: Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced that Mary Tagliaferri, M.D., has joined its Board of Directors. A [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease [...]

Washington: NEKTAR THERAPEUTICS, has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Mar 04, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in [...]

MINNEAPOLIS: DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following press release: Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, [...]

Jefferies slashed Nektar Therapeutics NKTR price target from $1.5 to $1. Jefferies analyst Roger Song upgraded the stock from Underperform to Hold. Nektar Therapeutics shares are down 1.89% to $0.75 [...]

NEW YORK: S&P Dow Jones Indices has issued the following news release: Crane Co. (NYSE:CR) will be added to the S&P MidCap 400 effective prior to the open of trading [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, [...]

Citigroup raised the price target for The Manitowoc Company, Inc. (NYSE:MTW) from $11 to $21. Citigroup analyst Timothy Thein maintained a Neutral rating. Morgan Stanley lowered REGENXBIO Inc. (NASDAQ:RGNX) from [...]

Oppenheimer has lowered Nektar Therapeutics NKTR price target from $5 to $3. Oppenheimer analyst Jay Olson maintained a Perform rating. Nektar Therapeutics shares are down 6.37% to $1.47 on the [...]

Nektar Therapeutics NKTR shares dropped 39.2% to $1.80 in pre-market trading after the company reported Phase 2 topline data for rezpegaldesleukin in patients with systemic lupus erythematosus. Ocean Biomedical Inc [...]

Nektar Therapeutics NKTR shares plunged 39.2% to $1.80 in pre-market trading after the company reported Phase 2 topline data for rezpegaldesleukin in patients with systemic lupus erythematosus. Ocean Biomedical Inc [...]

Fulcrum Therapeutics, Inc. FULC shares dropped 58% to $5.43 after the company announced a clinical hold on FTX-6058 in sickle cell disease. Shares of SELLAS Life Sciences Group, Inc. SLS [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics' President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P. Morgan [...]

NEW YORK: Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics breached their fiduciary duties to shareholders. The [...]

NEW YORK: Moore Kuehn, PLLC has issued the following news release: Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of [...]

NEW YORK: Moore Kuehn, PLLC has issued the following news release: Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of [...]

This Week (October 3, 2022 to October 7, 2022) was profitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it went up to $3.53 from the previous [...]

Shares of PureTech Health (NASDAQ:PRTC) traded lower on Friday after it confirmed receiving a non-binding proposal from Nektar Therapeutics (NASDAQ:NKTR) to combine. PureTech and Nektar remain in discussions regarding the [...]

This Week (September 26, 2022 to September 30, 2022) was profitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it went up to $3.2 from the previous [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics ( Nasdaq: NKTR) today announced data presentations from two Phase 1b, proof-of-concept studies of rezpegaldesleukin (also known as [...]

This Week (August 15, 2022 to August 19, 2022) was unprofitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it lowered down to $4.6 from the previous [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American [...]

This Week (August 1, 2022 to August 5, 2022) was profitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it went up to $4.88 from the previous [...]

This Week (July 18, 2022 to July 22, 2022) was profitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it went up to $3.68 from the previous [...]

Chicago: Sidley Austin has issued the following press release: On May 19, 2022, Sidley obtained a decisive victory in the United States Court of Appeals for the Ninth Circuit for [...]

This Week (May 9, 2022 to May 13, 2022) was unprofitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it lowered down to $3.99 from the previous [...]

This Week (April 25, 2022 to April 29, 2022) was unprofitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it lowered down to $4.13 from the previous [...]

SHANGHAI: I-Mab has issued the following news release: I-Mab ('I-Mab' or the 'Company') (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced [...]

This Week (April 18, 2022 to April 22, 2022) was profitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it went up to $4.56 from the previous [...]

NEW YORK: InvestorsObserver has issued the following news release: InvestorsObserver issues critical PriceWatch Alerts for DIDI, BRQS, ATER, NKTR, and TGTX. To see how InvestorsObserver's proprietary scoring system rates these [...]

PRINCETON: Nektar Therapeutics; Bristol Myers Squibb has issued the following news release: Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned [...]

This Week (April 4, 2022 to April 8, 2022) was unprofitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it lowered down to $5.51 from the previous [...]

1. Okta Inc. CI A collapsed to $156.78. The fall in price is $-12.63/-7.46%. 2. Upstart Holdings Inc. decreased to $118.50. The fall in price is $-7.35/-5.84%. 3. GoHealth Inc. [...]

This Week (March 14, 2022 to March 18, 2022) was profitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it went up to $5.6 from the previous [...]

PRINCETON: Bristol Myers Squibb and Nektar Therapeutics announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with [...]

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at [...]

This Week (March 7, 2022 to March 11, 2022) was profitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it went up to $10.63 from the previous [...]

WALTHAM: Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene therapies for rare and prevalent devastating diseases, announced the appointment of Diana [...]

This Week (February 28, 2022 to March 4, 2022) was profitable week for Nektar Therapeutics (NKTR) at NASDAQ Stock Market, in which it went up to $10.5 from the previous [...]